Noile-Immune Biotech Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Noile-Immune Biotech's earnings have been declining at an average annual rate of -15.6%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 27.3% per year.
Key information
-15.6%
Earnings growth rate
-11.0%
EPS growth rate
Biotechs Industry Growth | 31.9% |
Revenue growth rate | -27.3% |
Return on equity | -19.6% |
Net Margin | -319.2% |
Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Noile-Immune Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 307 | -980 | 460 | 783 |
31 Mar 24 | 310 | -976 | 449 | 666 |
31 Dec 23 | 316 | -1,130 | 404 | 646 |
30 Sep 23 | 319 | -1,268 | 400 | 569 |
31 Dec 22 | 625 | -386 | 390 | 334 |
31 Dec 21 | 100 | -795 | 330 | 514 |
31 Dec 20 | 97 | -636 | 285 | 413 |
Quality Earnings: 4893 is currently unprofitable.
Growing Profit Margin: 4893 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4893 is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.
Accelerating Growth: Unable to compare 4893's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4893 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 4893 has a negative Return on Equity (-19.58%), as it is currently unprofitable.